Esperion Therapeutics said its experimental drug showed greater reductions in cholesterol levels when compared with a placebo in a mid-stage study.
Patients taking doses of 120 mg and 180 mg of the drug, ETC-1002, showed 17 and 24 percent greater reduction in bad cholesterol levels.
The study was evaluating safety and effectiveness of the drug in patients with high cholesterol levels.